Investors should consider scooping up shares of this pharmaceutical giant trading at a discount, according to longtime value investor Bill Nygren.
Communicating your story to the Street
Investors should consider scooping up shares of this pharmaceutical giant trading at a discount, according to longtime value investor Bill Nygren.